The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Urovo Technology Co., Ltd. (SZSE:300531) share price slid 37% over twelve months. That's well below the market decline of 18%. Longer term shareholders haven't suffered as badly, since the stock is down a comparatively less painful 17% in three years. On top of that, the share price is down 11% in the last week.
If the past week is anything to go by, investor sentiment for Urovo Technology isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
Check out our latest analysis for Urovo Technology
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
During the unfortunate twelve months during which the Urovo Technology share price fell, it actually saw its earnings per share (EPS) improve by 8.6%. It's quite possible that growth expectations may have been unreasonable in the past.
The divergence between the EPS and the share price is quite notable, during the year. But we might find some different metrics explain the share price movements better.
Given the yield is quite low, at 0.4%, we doubt the dividend can shed much light on the share price. Revenue was fairly steady year on year, which isn't usually such a bad thing. But the share price might be lower because the market expected a meaningful improvement, and got none.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-17209325-0-09fefe205640718dcbce9e39f0c478be.png/big)
SZSE:300531 Earnings and Revenue Growth November 28th 2022
If you are thinking of buying or selling Urovo Technology stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
We regret to report that Urovo Technology shareholders are down 37% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 18%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 4% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Before forming an opinion on Urovo Technology you might want to consider these 3 valuation metrics.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CN exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
從上漲的市場中獲益的最簡單方式是購買指數基金。但如果你買入個股,你可以做得更好,也可以做得更差。不幸的是,烏羅沃科技有限公司。(SZSE:300531)股價在12個月內下滑了37%。這遠低於市場18%的跌幅。較長期股東的損失沒有那麼嚴重,因為該股在三年內下跌了17%,跌幅相對較小。最重要的是,該公司股價在過去一週下跌了11%。
如果以過去一週為標準,投資者對Urovo Technology的情緒並不樂觀,所以讓我們看看基本面和股價之間是否存在錯配。
查看我們對Urovo Technology的最新分析
雖然有效市場假説繼續被一些人傳授,但事實證明,市場是過度反應的動態系統,投資者並不總是理性的。通過比較每股收益(EPS)和股價隨時間的變化,我們可以感受到投資者對一家公司的態度隨着時間的推移發生了怎樣的變化。
不幸的是,在Urovo科技股價下跌的12個月裏,它的每股收益(EPS)實際上提高了8.6%。過去的增長預期很有可能是不合理的。
在這一年中,每股收益和股價之間的背離相當明顯。但我們可能會發現一些不同的衡量標準可以更好地解釋股價走勢。
鑑於收益率相當低,只有0.4%,我們懷疑股息能否對股價產生太大影響。營收與去年同期相比相當穩定,這通常不是一件壞事。但股價可能會更低,因為市場預計會出現有意義的改善,但沒有得到任何改善。
您可以在下圖中看到收益和收入隨時間的變化(單擊圖表查看確切的值)。
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-17209325-0-09fefe205640718dcbce9e39f0c478be.png/big)
深圳證交所:300531收益和收入增長2022年11月28日
如果你正在考慮購買或出售Urovo科技的股票,你應該看看這個免費關於其資產負債表的詳細報告。
不同的視角
我們遺憾地報告,Urovo Technology的股東今年以來下降了37%(甚至包括股息)。不幸的是,這比大盤18%的跌幅還要糟糕。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本面的發展。不幸的是,去年的表現可能預示着尚未解決的挑戰,因為它比過去五年4%的年化損失更糟糕。我們意識到,羅斯柴爾德男爵曾説過,投資者應該“在街上血淋淋的時候買入”,但我們警告投資者,首先應該確保他們購買的是一家高質量的企業。在對Urovo Technology形成看法之前,您可能需要考慮以下三個估值指標。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費已證明自己能夠實現盈利增長的公司名單。
請注意,本文引用的市場回報反映了目前在CN交易所交易的股票的市場加權平均回報。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。